SCHEMBL6437015

SCHEMBL6437015

Cc1ccc(Oc2ccccc2C(C)C)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 8/20 0.70
HTR2A P28223 6/20 0.70
AR P10275 1/20 0.48
LMNA P02545 1/20 0.47
HTT P42858 2/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
ALDH1A1 P00352 1/20 0.45
MAPK1 P28482 1/20 0.45
P2RX3 P56373 1/20 0.44
P2RX2 Q9UBL9 1/20 0.44
KCNH2 Q12809 3/20 0.43
SLC6A2 P23975 2/20 0.41
SLC6A3 Q01959 2/20 0.41
TEAD4 Q15561 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CES2 O00748 1/20 0.40
CES1 P23141 1/20 0.40
MEN1 O00255 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL123775 0.92 SLC6A4 (0.58) SLC6A4HTR2AARLMNAHTT
SCHEMBL6682183 0.86 SLC6A4 (0.51) SLC6A4HTR2AARLMNAHTT
SCHEMBL14047222 0.85 HTR2A (0.66) SLC6A4HTR2AARLMNAHTT
SCHEMBL5609460 0.85 ALDH1A1 (0.55) SLC6A4HTR2AARLMNAHTT
SCHEMBL13160049 0.85 SLC6A4 (0.54) SLC6A4HTR2AARHTTL3MBTL1
SCHEMBL18878420 0.85 SLC6A4 (0.51) SLC6A4HTR2AARLMNAHTT
SCHEMBL7950202 0.83 NCOA1 (0.51) SLC6A4HTR2AARHTTL3MBTL1
SCHEMBL5609057 0.83 HTR2A (0.71) SLC6A4HTR2AARLMNAHTT
SCHEMBL6061211 0.83 HTR2A (0.50) SLC6A4HTR2AARLMNAHTT
SCHEMBL2608310 0.81 HTT (0.65) SLC6A4HTR2AARLMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230139111-A1 DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) 2023-05-04 US disclosed
US-20100226882-A1 LINKED DIIMIDAZOLE ANTIVIRALS ENANTA PHARMACEUTICALS, INC. 2010-09-09 US disclosed
US-20050054882-A1 Diaryl ether condensation reactions NSF - DEITR 2005-03-10 US disclosed
US-6762329-B2 EFFECTS OF ACIDIC ACTIVATORS ON ULLMANN-TYPE COUPLINGS INVOLVING ELECTRON-POOR AND/OR RELATIVELY INSOLUBLE SUBSTRATES. MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2004-07-13 US disclosed
US-20030088128-A1 Diaryl ether condensation reactions NATIONAL SCIENCE FOUNDATION 2003-05-08 US disclosed
US-6395939-B1 CATALYTIC ETHERIFICATION AND CONDENSATION WITH COPPER CATALYSTS MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2002-05-28 US disclosed
WO-1999018057-A1 PREPARATION OF DIARYL ETHER BY CONDENSATION REACTIONS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1999-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100226882-A1 LINKED DIIMIDAZOLE ANTIVIRALS EIF2AK2, ZC3HAV1, MAVS SLC6A4 2759/4885HTR2A 4779/4885AR 4362/4885
US-20230139111-A1 DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF RIPK1, RIPK4, RIPK3 SLC6A4 1329/4885HTR2A 3594/4885AR 4443/4885
US-20050054882-A1 Diaryl ether condensation reactions NSFL1C, DERL1, UBE2M SLC6A4 4648/4885HTR2A 4316/4885AR 2280/4885
US-20030088128-A1 Diaryl ether condensation reactions NSFL1C, DERL1, UBE2M SLC6A4 4648/4885HTR2A 4316/4885AR 2280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.